Search

Your search keyword '"Pollock, Kevin G."' showing total 246 results
Start Over Author "Pollock, Kevin G."
246 results on '"Pollock, Kevin G."'

2. Undertaking multi-centre randomised controlled trials in primary care: learnings and recommendations from the PULsE-AI trial researchers

Author

Pollock, Kevin G., Dickerson, Carissa, Kainth, Manjit, Lawton, Sarah, Hurst, Michael, Sugrue, Daniel M., Arden, Chris, Davies, D. Wyn, Martin, Anne-Céline, Sandler, Belinda, Gordon, Jason, Farooqui, Usman, Clifton, David, Mallen, Christian, Rogers, Jennifer, Hill, Nathan R., Camm, A. John, and Cohen, Alexander T.

Published
2024
Full Text
View/download PDF

4. Investigating the feasibility of recruitment to an observational, quality-of-life study of patients diagnosed with atrial fibrillation (AF) who have experienced a bleed while anticoagulated: EQUAL-AF feasibility study protocol

Author

Hutchings, Hayley A., Lanyon, Kirsty, Lister, Steven, Alikhan, Raza, Halcox, Julian, Holland, Gail, Hughes, Arfon, Jenkins, Rhys, Laing, Hamish, Lobban, Trudie, Owen, Diane, Pollock, Kevin G., Todd, Ceri, and Wareham, Kathie

Published
2022
Full Text
View/download PDF

9. List of Contributors

Author

Alemany, Laia, primary, Arbyn, Marc, additional, Beeravolu, Harshita, additional, Bergeron, Christine, additional, Berkhof, Johannes, additional, Bhatla, Neerja, additional, Bosch, F. Xavier, additional, Broker, Thomas R., additional, Bruni, Laia, additional, Canarte, Veronica, additional, Canfell, Karen, additional, Corcoran, Brenda, additional, Cubie, Heather, additional, Cuschieri, Kate, additional, Cuzick, J., additional, Denny, Lynette, additional, Doorbar, John, additional, Dutta, Tapati, additional, Fakhry, Carole, additional, Faraji, Farhoud, additional, Forster, Alice, additional, Franceschi, Silva, additional, Franco, Eduardo L., additional, Garland, Suzanne M., additional, Geraets, Daan, additional, Giuliano, Anna R., additional, Grace, Miranda, additional, Guimera, Nuria, additional, Hanley, Sharon, additional, Heideman, D.A.M., additional, Jenkins, David, additional, Joura, Elmar, additional, Kremer, W.W., additional, Lacey, Charles J.N., additional, Leeman, Annemiek, additional, Lorincz, Attila, additional, Markowitz, Lauri E., additional, Meijer, Chris J.L.M., additional, Meyerson, Beth E., additional, Moscicki, Anna-Barbara, additional, Munger, Karl, additional, Muñoz, Nubia, additional, Paavonen, Jorma, additional, Palefsky, Joel M., additional, Pollock, Kevin G., additional, Quint, Wim, additional, Ronco, G., additional, Schiffman, Mark, additional, Sharma, Surendra, additional, Singer, Albert, additional, Stanley, Margaret, additional, Stoler, Mark H., additional, von Knebel Doeberitz, Magnus, additional, Wheeler, Cosette Marie, additional, Wu, Sharon C., additional, and Zimet, Gregory D., additional

Published
2020
Full Text
View/download PDF

11. Novel Approaches for Vaccination Against HPV-Induced Cancers

Author

King, Emma, Ottensmeier, Christian, Pollock, Kevin G. J., Compans, Richard W, Series editor, Honjo, Tasuku, Series editor, Oldstone, Michael B. A., Series editor, Vogt, Peter K., Series editor, Malissen, Bernard, Series editor, Aktories, Klaus, Series editor, Kawaoka, Yoshihiro, Series editor, Rappuoli, Rino, Series editor, Galan, Jorge E., Series editor, Ahmed, Rafi, Series editor, Palme, Klaus, Series editor, Casadevall, Arturo, Series editor, Garcia-Sastre, Adolfo, Series editor, Savelyeva, Natalia, editor, and Ottensmeier, Christian, editor

Published
2017
Full Text
View/download PDF

12. Development of a Cross-Cultural HPV Community Engagement Model within Scotland

Author

Carnegie, Elaine, Whittaker, Anne, Gray Brunton, Carol, Hogg, Rhona, Kennedy, Catriona, Hilton, Shona, Harding, Seeromanie, Pollock, Kevin G., and Pow, Janette

Abstract

Objective: To examine cultural barriers and participant solutions regarding acceptance and uptake of the human papillomavirus (HPV) vaccine from the perspective of Black African, White-Caribbean, Arab, Indian, Bangladeshi and Pakistani young people. Methods: In total, 40 young people from minority ethnic communities in Scotland took part in a qualitative study, involving seven focus groups and four paired interviews, to explore their views and experiences of the HPV vaccine. Using critical discursive psychology, the analysis focused on young people's accounts of barriers and enablers to information, access and uptake of the HPV vaccination programme. Results: Participants suggested innovative strategies to tackle intergenerational concerns, information design and accessibility, and public health communications across diverse contexts. A cross-cultural community engagement model was developed, embracing diversity and contradiction across different ethnic groups. This included four inter-related strategies: providing targeted and flexible information for young people, vaccine provision across the life-course, intergenerational information and specific cross-cultural communications. Conclusion: This is the first HPV cross-cultural model inductively derived from accounts of young people from different ethnic communities. We recommend public health practitioners and policymakers consider using the processes and strategies within this model to increase dialogue around public engagement, awareness and receptivity towards HPV vaccination.

Published
2017
Full Text
View/download PDF

16. An Update on Anti-thrombotic Therapy Following Transcatheter Aortic Valve Implantation: Expert Cardiologist Opinion from a UK and Ireland Delphi Group

Author

Zaman, Azfar, primary, Prendergast, Bernard, additional, Hildick-Smith, David, additional, Blackman, Daniel, additional, Anderson, Richard, additional, Spence, Mark S, additional, Mylotte, Darren, additional, Smith, David, additional, Wilding, Ben, additional, Chapman, Chris, additional, Atkins, Kirsty, additional, Pollock, Kevin G, additional, Qureshi, Ayesha C, additional, and Banning, Adrian, additional

Published
2023
Full Text
View/download PDF

17. Sex Differences in Oral Anticoagulation Therapy in Patients Hospitalized With Atrial Fibrillation: A Nationwide Cohort Study

Author

Lee, Kuan Ken, primary, Doudesis, Dimitrios, additional, Bing, Rong, additional, Astengo, Federica, additional, Perez, Jesus R., additional, Anand, Atul, additional, McIntyre, Shauna, additional, Bloor, Nicholas, additional, Sandler, Belinda, additional, Lister, Steven, additional, Pollock, Kevin G., additional, Qureshi, Ayesha C., additional, McAllister, David A., additional, Shah, Anoop S. V., additional, and Mills, Nicholas L., additional

Published
2023
Full Text
View/download PDF

18. A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK

Author

Cohen, Alexander T., primary, Benson, Gary, additional, Bradbury, Charlotte A., additional, Choudhuri, Satarupa, additional, Hutchinson Jones, Nathan, additional, Maraveyas, Anthony, additional, Venugopal, Balaji, additional, Young, Annie M., additional, Chapman, Chris, additional, McIntyre, Shauna, additional, Burney, Danny, additional, Pollock, Kevin G., additional, Morgan, Angharad R., additional, Gabb, Peter D., additional, and Alikhan, Raza, additional

Published
2023
Full Text
View/download PDF

19. Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014–2019)

Author

Joy, Mark, primary, Williams, John, additional, Emanuel, Subo, additional, Kar, Debasish, additional, Fan, Xuejuan, additional, Delanerolle, Gayathri, additional, Field, Benjamin CT, additional, Heiss, Christian, additional, Pollock, Kevin G, additional, Sandler, Belinda, additional, Arora, Jasleen, additional, Sheppard, James P, additional, Feher, Michael, additional, Hobbs, FD Richard, additional, and de Lusignan, Simon, additional

Published
2022
Full Text
View/download PDF

20. Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes

Author

Mesher, David, Soldan, Kate, Lehtinen, Matti, Beddows, Simon, Brisson, Marc, Brotherton, Julia M.L., Chow, Eric P.F., Cummings, Teresa, Drolet, Melanie, Fairley, Christopher K., Garland, Suzanne M., Kahn, Jessica A., Kavanagh, Kimberley, Markowitz, Lauri, Pollock, Kevin G., Soderlund-Strand, Anna, Sonnenberg, Pam, Tabrizi, Sepehr N., Tanton, Clare, Unger, Elizabeth, and Thomas, Sara L.

Subjects
Vaccination -- Health aspects, Papillomaviruses -- Genetic aspects -- Health aspects, Genotype -- Health aspects, Health
Abstract

Persistent infection with a high-risk human papillomavirus (HPV) genotype is necessary for development of cervical cancer (1). Two high-risk types, HPV16 and HPV18, cause ≅70%-80% of cervical cancers (2-4). The [...]

Published
2016
Full Text
View/download PDF

21. Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evaluated in a randomized controlled trial in England

Author

Hill, Nathan R., primary, Groves, Lara, additional, Dickerson, Carissa, additional, Boyce, Rebecca, additional, Lawton, Sarah, additional, Hurst, Michael, additional, Pollock, Kevin G., additional, Sugrue, Daniel M., additional, Lister, Steven, additional, Arden, Chris, additional, Davies, D. Wyn, additional, Martin, Anne-Celine, additional, Sandler, Belinda, additional, Gordon, Jason, additional, Farooqui, Usman, additional, Clifton, David, additional, Mallen, Christian, additional, Rogers, Jennifer, additional, Camm, A. John, additional, and Cohen, Alexander T., additional

Published
2022
Full Text
View/download PDF

25. Identification of undiagnosed atrial fibrillation using a machine learning risk-prediction algorithm and diagnostic testing (PULsE-AI) in primary care: a multi-centre randomized controlled trial in England

Author

Hill, Nathan R, primary, Groves, Lara, additional, Dickerson, Carissa, additional, Ochs, Andreas, additional, Pang, Dong, additional, Lawton, Sarah, additional, Hurst, Michael, additional, Pollock, Kevin G, additional, Sugrue, Daniel M, additional, Tsang, Carmen, additional, Arden, Chris, additional, Wyn Davies, David, additional, Martin, Anne Celine, additional, Sandler, Belinda, additional, Gordon, Jason, additional, Farooqui, Usman, additional, Clifton, David, additional, Mallen, Christian, additional, Rogers, Jennifer, additional, Camm, Alan John, additional, and Cohen, Alexander T, additional

Published
2022
Full Text
View/download PDF

27. Additional file 1 of Investigating the feasibility of recruitment to an observational, quality-of-life study of patients diagnosed with atrial fibrillation (AF) who have experienced a bleed while anticoagulated: EQUAL-AF feasibility study protocol

Author

Hutchings, Hayley A., Lanyon, Kirsty, Lister, Steven, Alikhan, Raza, Halcox, Julian, Holland, Gail, Hughes, Arfon, Jenkins, Rhys, Laing, Hamish, Lobban, Trudie, Owen, Diane, Pollock, Kevin G., Todd, Ceri, and Wareham, Kathie

Abstract

Additional file 1: EQUAL-AF Interview Questions.

Published
2022
Full Text
View/download PDF

30. Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019).

Author

Joy, Mark, Williams, John, Emanuel, Subo, Kar, Debasish, Xuejuan Fan, Delanerolle, Gayathri, Field, Benjamin C. T., Heiss, Christian, Pollock, Kevin G., Sandler, Belinda, Arora, Jasleen, Sheppard, James P., Feher, Michael, Hobbs, Richard, de Lusignan, Simon, Fan, Xuejuan, Field, Benjamin Ct, and Hobbs, Fd Richard

Subjects
ORAL medication, DRUG prescribing, ANTICOAGULANTS, PRIMARY care, ELECTRONOGRAPHY, ATRIAL fibrillation
Abstract

Background: In England, most prescribing of direct-acting oral anticoagulants for atrial fibrillation (AF) is in primary care. However, there remain gaps in our understanding of dosage and disparities in use. We aimed to describe trends in direct oral anticoagulant (DOAC) prescribing, including dose reduction in people with renal impairment and other criteria, and adherence.Methods: Using English primary care sentinel network data from 2014 to 2019, we assessed appropriate DOAC dose adjustment with creatinine clearance (CrCl). Our primary care sentinel cohort was a subset of 722 general practices, with 6.46 million currently registered patients at the time of this study.Results: Of 6 464 129 people in the cohort, 2.3% were aged ≥18 years with a diagnosis of AF, and 30.8% of these were prescribed vitamin K antagonist and 69.1% DOACs. Appropriate DOAC prescribing following CrCl measures improved between 2014 and 2019; dabigatran from 21.3% (95% CI 15.1% to 28.8%) to 48.7% (95% CI 45.0% to 52.4%); rivaroxaban from 22.1% (95% CI 16.7% to 28.4%) to 49.9% (95% CI 48.5% to 53.3%); edoxaban from 10.0% (95% CI 0.3% to 44.5%) in 2016 to 57.6% (95% CI 54.5% to 60.7%) in 2019; apixaban from 30.8% (95% CI 9.1% to 61.4%) in 2015 to 60.5% (95% CI 57.8% to 63.2%) in 2019.Adherence was highest for factor Xa inhibitors, increasing from 50.1% (95% CI 47.7% to 52.4%) in 2014 to 57.8% (95% CI 57.4% to 58.2%) in 2019. Asian and black/mixed ethnicity was associated with non-adherence (OR 1.81, 95% CI 1.56 to 2.09) as was male gender (OR 1.19, 95% CI 1.15 to 1.22), higher socioeconomic status (OR 1.60, 95% CI 1.52 to 1.68), being an ex-smoker (OR 1.12, 95% CI 1.06 to 1.19) and hypertension (OR 1.07, 95% CI 1.03 to 1.17).Conclusions: The volume and quality of DOAC prescribing has increased yearly. Future interventions to augment quality of anticoagulant management should target disparities in adherence. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Feasibility Study Protocol: Investigating The Impact of Bleed Events On Anticoagulated Patients Diagnosed With Atrial Fibrillation Using Patient Reported Outcome Measures

Author

Hutchings, Hayley A, primary, Lanyon, Kirsty, additional, Lister, Steven, additional, Alikhan, Raza, additional, Fegan, Claire, additional, Halcox, Julian, additional, Holland, Gail, additional, Hughes, Arfon, additional, Jenkins, Rhys, additional, Laing, Hamish, additional, Lobban, Trudie, additional, More, Lianne, additional, Owen, Diane, additional, Pollock, Kevin G, additional, Todd, Ceri, additional, and Wareham, Kathie, additional

Published
2021
Full Text
View/download PDF

35. Additional file 1 of Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study

Author

Choy, Ernest, Groves, Lara, Sugrue, Daniel, Hurst, Michael, Houghton, John, Srinivasan Venkatachalam, Patel, Yusuf I., Maxwell, James R., Pollock, Kevin G., and Henning, Sadie

Abstract

Additional file 1: Table S1. EULAR response for abatacept vs other bDMARDs at 6 and 12 months after LOT initiation. Table S2. Summary of missingness for key baseline demographic and clinical variables at index. Table S3. DAS score change from LOT initiation missingness.

Published
2021
Full Text
View/download PDF

36. Using machine learning to predict anticoagulation control in atrial fibrillation: A UK Clinical Practice Research Datalink study

Author

Gordon, Jason, primary, Norman, Max, additional, Hurst, Michael, additional, Mason, Thomas, additional, Dickerson, Carissa, additional, Sandler, Belinda, additional, Pollock, Kevin G., additional, Farooqui, Usman, additional, Groves, Lara, additional, Tsang, Carmen, additional, Clifton, David, additional, Bakhai, Ameet, additional, and Hill, Nathan R., additional

Published
2021
Full Text
View/download PDF

38. Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): Study protocol for a randomised controlled trial

Author

Hill, Nathan R., primary, Arden, Chris, additional, Beresford-Hulme, Lee, additional, Camm, A. John, additional, Clifton, David, additional, Davies, D. Wyn, additional, Farooqui, Usman, additional, Gordon, Jason, additional, Groves, Lara, additional, Hurst, Michael, additional, Lawton, Sarah, additional, Lister, Steven, additional, Mallen, Christian, additional, Martin, Anne-Celine, additional, McEwan, Phil, additional, Pollock, Kevin G., additional, Rogers, Jennifer, additional, Sandler, Belinda, additional, Sugrue, Daniel M., additional, and Cohen, Alexander T., additional

Published
2020
Full Text
View/download PDF

42. A prospective cohort study of HPV-driven oropharyngeal cancers; implications for prognosis and immunisation

Author

Wakeham, Katie, Pan, Jiafeng, Pollock, Kevin G J, Millan, David, Bell, Sarah, McLellen, Douglas, McPhaden, Allan, Conway, David I, Graham, Sheila V, Kavanagh, Kim, and Cuschieri, Kate

Subjects
RC0254
Abstract

Oropharyngeal cancer (OPC) is increasing on a global scale, including the component driven by high-risk human papillomavirus (HR-HPV); contemporary data that provide insight into the prognosis of this disease in addition to the fraction attributable to HR-HPV are essential to inform primary and secondary disease management strategies. A population-based cohort of 235 patients diagnosed with OPC between 2013-15 in Scotland was assessed for HPV status using molecular genotyping. Associations between HR-HPV status and key clinical and demographic variables were estimated using the Pearson chi-squared test. Rates of overall survival (OS) and progression-free survival (PFS) were estimated and visualized using Kaplan–Meier curves. HPV DNA (largely HPV 16) was identified in 60% of cases. After adjustment for age, gender, deprivation, smoking, alcohol consumption and tumour stage, patients with HR-HPV positive OPC had 89% reduction in risk of death (HR = 0.11, 95% CI 0.05-0.25), and an 85% reduction in risk of disease progression (HR = 0.15 95% CI 0.07-0.30). HPV positivity was not associated with age, deprivation or smoking status, whereas those who reported excess alcohol consumption were less likely to be HPV positive. The prevalence of HPV-associated OPC is high in Scotland and strongly associated with dramatically improved clinical outcomes including survival. Demographic/behavioural variables did not reliably predict HPV positivity in this cohort which underlines the importance of laboratory confirmation. Finally, the dominance of HPV 16 in OPC indicates the significant impact of prophylactic immunisation on this disease.

Published
2019

45. Real‐world impact following initiation of interferon‐free hepatitis C regimens on liver‐related outcomes and all‐cause mortality among patients with compensated cirrhosis

Author

McDonald, Scott A., primary, Pollock, Kevin G., additional, Barclay, Stephen T., additional, Goldberg, David J., additional, Bathgate, Andrew, additional, Bramley, Peter, additional, Dillon, John F., additional, Fraser, Andrew, additional, Innes, Hamish A., additional, Kennedy, Nicholas, additional, Morris, Judith, additional, Went, April, additional, Hayes, Peter C., additional, and Hutchinson, Sharon J., additional

Published
2019
Full Text
View/download PDF

46. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis

Author

Drolet, Mélanie, primary, Bénard, Élodie, additional, Pérez, Norma, additional, Brisson, Marc, additional, Ali, Hammad, additional, Boily, Marie-Claude, additional, Baldo, Vincenzo, additional, Brassard, Paul, additional, Brotherton, Julia M L, additional, Callander, Denton, additional, Checchi, Marta, additional, Chow, Eric P F, additional, Cocchio, Silvia, additional, Dalianis, Tina, additional, Deeks, Shelley L, additional, Dehlendorff, Christian, additional, Donovan, Basil, additional, Fairley, Christopher K, additional, Flagg, Elaine W, additional, Gargano, Julia W, additional, Garland, Suzanne M, additional, Grün, Nathalie, additional, Hansen, Bo T, additional, Harrison, Christopher, additional, Herweijer, Eva, additional, Imburgia, Teresa M, additional, Johnson, Anne M, additional, Kahn, Jessica A, additional, Kavanagh, Kimberley, additional, Kjaer, Susanne K, additional, Kliewer, Erich V, additional, Liu, Bette, additional, Machalek, Dorothy A, additional, Markowitz, Lauri, additional, Mesher, David, additional, Munk, Christian, additional, Niccolai, Linda, additional, Nygård, Mari, additional, Ogilvie, Gina, additional, Oliphant, Jeannie, additional, Pollock, Kevin G, additional, Purriños-Hermida, Maria Jesús, additional, Smith, Megan A, additional, Steben, Marc, additional, Söderlund-Strand, Anna, additional, Sonnenberg, Pam, additional, Sparen, Pär, additional, Tanton, Clare, additional, Wheeler, Cosette M, additional, Woestenberg, Petra J, additional, and Yu, Bo Nancy, additional

Published
2019
Full Text
View/download PDF

48. Increased risk of HPV‐associated genital cancers in men and women as a consequence of pre‐invasive disease

Author

Pan, Jiafeng, primary, Kavanagh, Kimberley, additional, Cuschieri, Kate, additional, Pollock, Kevin G., additional, Gilbert, Duncan C., additional, Millan, David, additional, Bell, Sarah, additional, Graham, Sheila V., additional, Williams, Alistair R.W., additional, Cruickshank, Margaret E., additional, Palmer, Tim, additional, and Wakeham, Katie, additional

Published
2019
Full Text
View/download PDF

50. Changes in HPV prevalence following a national bivalent HPV vaccination programme in Scotland: a 7-year cross-sectional study

Author

Kavanagh, Kimberley, Pollock, Kevin G J, Cuschieri, Kate, Palmer, Timothy, Cameron, Ross L., Watt, D. Cameron, Bhatia, Ramya, Moore, Catherine, Cubie, Heather, Cruickshank, Margaret E, and Robertson, Chris

Abstract

BACKGROUND: On Sept 1, 2008, Scotland launched routine vaccination for human papillomavirus (HPV) types 16 and 18, targeted at 12-13-year-old girls, of whom 92·4% were fully vaccinated in 2008-09. In this study, we report on vaccine effectiveness of the bivalent vaccine in these vaccinated women who attended for routine cervical screening at age 20-21 years.METHODS: In this 7-year cross-sectional study (covering birth cohorts 1988-1995), we sampled approximately 1000 samples per year from those attending cervical screening at age 20-21 years and tested each for HPV. By linkage to vaccination records we ascertained prevalence by birth cohort and vaccination status. Estimates of vaccine effectiveness for HPV types 16 and 18, HPV types 31, 33, and 45, other high-risk types, and any HPV were calculated using logistic regression.FINDINGS: In total, 8584 samples were HPV genotyped. Prevalence of HPV types 16 and 18 reduced substantially from 30·0% (95% CI 26·9-33·1) in the 1988 cohort to 4·5% (3·5-5·7) in the 1995 cohort, giving a vaccine effectiveness of 89·1% (85·1-92·3) for those vaccinated at age 12-13 years. All cross-protective types showed significant vaccine effectiveness (HPV type 31, 93·8% [95% CI 83·8-98·5]; HPV type 33, 79·1% [64·2-89·0]; HPV type 45, 82·6% [61·5-93·9]). Unvaccinated individuals born in 1995 had a reduced odds of HPV types 16 and 18 infection compared with those born in 1988 (adjusted odds ratio 0·13 [95% CI 0·06-0·28]) and reduced odds of HPV types 31, 33, and 45 (odds ratio 0·45 [0·23-0·89]).INTERPRETATION: Bivalent vaccination has led to a startling reduction in vaccine and cross-protective HPV types 7 years after vaccination. There is also evidence of herd protection against the vaccine-specific and cross-protective types in unvaccinated individuals born in 1995. These findings should be considered in cost-effectiveness models informing vaccine choice and models to shape the future of cervical screening programmes.FUNDING: Scottish Government and Chief Scientists Office.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results